Sumec Corporation Limited (SHA:600710)

Checkpoint Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	116,124	116,972	122,741	140,986	167,804	98,153
Other Revenue	202.5	202.5	275.81	162.07	878.45	436.95
Revenue	116,327	117,174	123,017	141,148	168,682	98,590
Revenue Growth (YoY)	1.64%	-4.75%	-12.85%	-16.32%	71.09%	15.08%
Cost of Revenue	108,204	109,242	116,267	134,446	162,215	93,115
Gross Profit	8,123	7,932	6,750	6,702	6,467	5,475
Selling, General & Admin	2,845	2,845	2,603	2,416	2,296	2,298
Research & Development	382.87	382.87	496.56	462.42	474.99	366.32
Other Operating Expenses	133.33	133.33	144.36	117.19	88.58	63.95
Operating Expenses	3,504	3,504	3,263	3,185	2,904	2,932
Operating Income	4,619	4,428	3,487	3,517	3,563	2,543
Interest Expense	-263.03	-263.03	-265.82	-381.44	-500.37	-436.98
Interest & Investment Income	333.04	333.04	370.04	340.2	221.68	135.12
Currency Exchange Gain (Loss)	-86.91	-86.91	-22.18	180.73	165.53	-54.78
Other Non Operating Income (Expenses)	-52.89	-23.59	-15.36	-75.69	-90.86	-31.5
EBT Excluding Unusual Items	4,549	4,387	3,554	3,580	3,359	2,155
Impairment of Goodwill	-0.61	-0.61	-7.26	-49.97	-	-
Gain (Loss) on Sale of Investments	6.01	6.01	3.41	-0.84	32.2	54.09
Gain (Loss) on Sale of Assets	6.55	6.55	44.98	160.24	3.32	4.9
Asset Writedown	-429.12	-429.12	-7.51	-129.74	-277.56	-11.92
Legal Settlements	-	-	10.77	36.48	-	-
Other Unusual Items	184.98	184.98	356.16	175.3	42.55	25.85
Pretax Income	4,317	4,155	3,954	3,772	3,159	2,228
Income Tax Expense	987.28	898.23	855.72	901.32	769.5	552.02
Earnings From Continuing Operations	3,329	3,257	3,099	2,871	2,390	1,676
Minority Interest in Earnings	-2,109	-2,109	-2,070	-1,958	-1,623	-1,130
Net Income	1,221	1,148	1,028	912.85	767.07	546.22
Net Income to Common	1,221	1,148	1,028	912.85	767.07	546.22
Net Income Growth	11.85%	11.69%	12.63%	19.00%	40.43%	20.92%
Shares Outstanding (Basic)	1,312	1,305	1,301	1,304	1,300	1,301
Shares Outstanding (Diluted)	1,312	1,305	1,301	1,304	1,300	1,301
Shares Change (YoY)	1.00%	0.27%	-0.20%	0.30%	-0.03%	0.77%
EPS (Basic)	0.93	0.88	0.79	0.70	0.59	0.42
EPS (Diluted)	0.93	0.88	0.79	0.70	0.59	0.42
EPS Growth	10.75%	11.39%	12.86%	18.64%	40.48%	20.00%
Free Cash Flow	-	5,019	2,479	5,956	5,389	3,300
Free Cash Flow Per Share	-	3.85	1.91	4.57	4.14	2.54
Dividend Per Share	0.369	0.369	0.330	0.300	0.265	0.251
Dividend Growth	11.82%	11.82%	10.00%	13.21%	5.58%	146.08%
Gross Margin	6.98%	6.77%	5.49%	4.75%	3.83%	5.55%
Operating Margin	3.97%	3.78%	2.83%	2.49%	2.11%	2.58%
Profit Margin	1.05%	0.98%	0.84%	0.65%	0.46%	0.55%
Free Cash Flow Margin	-	4.28%	2.02%	4.22%	3.19%	3.35%
EBITDA	5,161	4,930	4,014	4,094	4,200	3,351
EBITDA Margin	4.44%	4.21%	3.26%	2.90%	2.49%	3.40%
D&A For EBITDA	542.88	502.61	526.55	576.97	637.1	807.7
EBIT	4,619	4,428	3,487	3,517	3,563	2,543
EBIT Margin	3.97%	3.78%	2.83%	2.49%	2.11%	2.58%
Effective Tax Rate	22.87%	21.62%	21.64%	23.89%	24.36%	24.78%
Revenue as Reported	117,174	117,174	123,017	141,148	168,682	98,590
Advertising Expenses	-	74.36	83.82	63.58	50.93	45.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.